Capitainer AB

Today we have some really good news to share 🥳  We have just launched the new innovative sampling card Capitainer®SEP10 - the ultimate at-home sampling product for separated blood from a finger prick. It is with pride we make this addition to our family of at-home blood sampling cards. Capitainer®SEP10 is meeting a since long existed demand on the market - at-home collection of plasma.   Capitainer®SEP10 is slim and smart, automating the entire collection process; ✅ Measurement of exact blood volume ✅ Separation of blood cells from the liquid ✅ No test tubes ✅ No disposable gloves ✅ No syringes ✅ No trained phlebotomist ✅ No centrifuge ✅ Indication of sample success Read the full release and here you can find out more about the benefits and new opportunities this opens for diagnostic, research and clinical trials users. https://lnkd.in/dPeMARmx https://lnkd.in/dTTvXXf4

We’re excited to announce that Capitainer's complete self-sampling kits, now MDR compliant, are available to our partners within the EU and the UK. These kits include everything needed for safe and convenient self-sampling from home, allowing healthcare providers to offer patients a simpler way to manage health checks without a clinic visit. As Mikael Ström, Business Development Director at Capitainer, highlights: “By offering a complete solution, we can better meet our customers’ needs and expectations, allowing them to reach patients more efficiently.” Learn more here: https://lnkd.in/dFGk_bpa #Capitainer #SelfSampling #MedTech #HealthcareInnovation #PatientCare

Professor Henrik Zetterberg shares his vision of conducting global molecular epidemiological studies on neurodegenerative dementias, now made possible through our new device, Capitainer®SEP10. Quantitative dried plasma microsampling enables large-scale sampling and analysis of blood biomarkers, accelerating our understanding of neurodegenerative diseases. #alzheimers #neurodegenerative diseases #microsampling

We are happy to welcome Kristina Thomsen Hall as our new Chief Financial Officer! Kristina brings over 10 years of financial management experience from various international companies, including roles as CFO at Chinsay and Finance Director at Sea by Maritech. Her expertise spans financial planning, analysis, M&A, and corporate restructuring, making her an excellent addition to our team as we continue to pursue our strategic goals. "Her extensive experience and proven track record in financial management make her an ideal fit for Capitainer as we continue to execute our strategic plan and drive long-term value," says CEO Christopher Aulin. We also want to thank Kerstin Widman for her dedication over the past four years and wish her all the best in her future endeavors! Read the full press release here: https://lnkd.in/ga3qyxQW   #medtech #healthcareinnovation #capitainer #selfsampling

Are you interested in elemental analysis solutions? Sign up for this webinar series from Thermo Fisher Scientific, on their cutting-edge ICP-MS and ICP-OES solutions. The seminar on the 16th of October, is hosted at Capitainer and in our microsampling laboratory miQro Lab Solutions, Rhode Island, USA. The laboratory is led by our principle sccientist Donald Chace who is the director of the lab. If you want to learn more about microsampling with Capitainer for elemental analysis and what services that can be offered at miQro, equiped with Thermo Fishers ICP-MS solution, please reach out to us via [email protected]. #icpms #exposome #microsampling #ElementalAnalysis #environmentalmonitoring

What does the future of Alzheimer’s disease diagnostics look like? Professor Henrik Zetterberg shares his perspectives and research on developing next-generation diagnostics for Alzheimer’s, article: https://lnkd.in/dYtUaCeq In the clip, Professor Zetterberg discusses quantitative dried plasma microsampling technology - with only a few drops of dried blood from a finger prick, it’s possible to measure all key blood biomarkers for Alzheimer’s disease, by using ultra-sensitive multiplex technology NULISA (Alamar Biosciences, Inc.). These dried blood samples provide results that align with traditional venous blood draws. These biomarkers are stable in room temperature for up to six months. This opens the door to democratizing Alzheimer’s diagnostics by enabling remote testing, even in areas far from labs.   Professor Zetterberg and his team has used Capitainer®B50 and been one of the first users, pre-launch, of our new device Capitainer®SEP10.

Dried blood microsampling has vast application areas and provides a fantastic opportunity for more person-centric sampling solutions. However, the composition of whole blood is highly complex, which limits the use of whole blood samples since some clinical laboratory analyses requires the separation of the cell fraction. For quantitative analysis of certain analytes, e.g., potassium, plasma is the only suitable sampling matrix since sampling in whole blood does not yield reliable results. Plasma is also used to monitor the concentrations of experimental drugs and their metabolites during clinical trials for new candidate drugs, since it harbours the drug fraction most relevant for studying the pharmacokinetic and pharmacodynamic effects of the experimental drug. In this article, we describe the needs and also several requirements that must be met to make microsampling of separated blood available. Read the post and stay tuned with Capitainer for more news about microsampling for a separated blood matrix. #microsampling #HealthTechInnoation https://lnkd.in/dtKxyPay

Decentralised clinical trials gained momentum during the COVID-19 pandemic, and their prevalence continues to grow rapidly. In contrast to centralised or conventional clinical trials, which require study participants to take part ’in person’, decentralised clinical trials allow remote participation using state-of-the-art digital health technologies. In this article, we compare centralised and decentralised clinical trials, briefly overview how decentralised trials are performed, and outline their advantages over conventional trials. Reach out to us and talk to the Capitainer team of sampling and application specialists, to learn how our sampling solution can help to make your study better. #clinicaltrial #microsampling #decentralizedclinicaltrials #patientcentricity #decentralizedtrials https://lnkd.in/dhW297wV

A method for PFAS testing with Capitainer has been developed. The European Environment Agency state in the report “Risks of PFAS for human health in Europe” from 2024 that “Future human biomonitoring will be essential to track long-term trends of previously- and currently-used chemicals like PFAS”. As a background, the report states that “Teenagers in Europe face health risks from exposure to toxic per- and polyfluoroalkyl substances (PFAS) according to a series of studies conducted between 2014 and 2021. Of the teenagers who participated in the studies, an average of 14.3% had blood levels above the health-based guidance value (HBGV), with two countries exceeding 20%.” In a recent publication from University of Turin, the researchers developed a method to test blood levels of PFAS from microsamples collected with Capitainer. The developed method can detect and quantify 25 different PFAS from only 10µL of dried blood. This development enables efficient and easy testing programs with at-home sampling, that perfectly could meet the needs of biomonitoring stated in the report from the European Environmental Agency. Thank you Martina Galletto and Alberto Salomone, for excellent development work. Their paper is available in the link below. Contact us at Capitainer if you want to learn more about human biomonitoring using our sampling solution. #exposome #PFAS #microsampling Link to the report from the European Environment Agency is available here: https://lnkd.in/dXx4tpRn https://lnkd.in/dxb6ZhWc

A method for PFAS testing with Capitainer has been developed. The European Environment Agency state in the report “Risks of PFAS for human health in Europe” from 2024 that “Future human biomonitoring will be essential to track long-term trends of previously- and currently-used chemicals like PFAS”. As a background, the report states that “Teenagers in Europe face health risks from exposure to toxic per- and polyfluoroalkyl substances (PFAS) according to a series of studies conducted between 2014 and 2021. Of the teenagers who participated in the studies, an average of 14.3% had blood levels above the health-based guidance value (HBGV), with two countries exceeding 20%.” In a recent publication from University of Turin, the researchers developed a method to test blood levels of PFAS from microsamples collected with Capitainer. The developed method can detect and quantify 25 different PFAS from only 10µL of dried blood. This development enables efficient and easy testing programs with at-home sampling, that perfectly could meet the needs of biomonitoring stated in the report from the European Environmental Agency. Thank you Martina Galletto and Alberto Salomone, for excellent development work. Their paper is available in the link below. Contact us at Capitainer if you want to learn more about human biomonitoring using our sampling solution. #exposome #PFAS #microsampling Link to the report from the European Environment Agency is available here: https://lnkd.in/dXx4tpRn https://lnkd.in/dxb6ZhWc